Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion”…
Seeking Investors: First-in-Class Immunotherapeutics for Cancer
ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Cambium Oncology is pleased to share…
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine…
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine…
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
-- Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of…
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
This is the second asset Menarini Group has inlicensed from Insilico Medicine…
X-tosis to Present at Seed Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference
GAINESVILLE, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- X-tosis, Inc., a pre-clinical…
Veeda Group Rebrands as ‘Veeda Lifesciences’
AHMEDABAD, India, Jan. 2, 2025 /PRNewswire/ -- Veeda Group has unveiled a…
MiNA Therapeutics Presents New Pre-Clinical Data from Lead Sickle Cell Disease Program at the American Society of Hematology Annual Meeting
MTL-HBG drug candidate demonstrated best-in-class activity and safety in pre-clinical models Data…
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
December 07, 2024 12:00 ET | Source: Y-mAbs Therapeutics, Inc. NEW YORK,…